Coherus Oncology reports FY2025 net loss $183.1M; LOQTORZI revenue doubles to $40.8M

Coherus Oncology, Inc.

LOQTORZI net revenue $40.8M in 2025, more than double $19.1M in 2024; Q4 net revenue $12.4M up 11% QoQ.
Total debt reduced 90% from $480M to $38.8M during 2024-2025; year-end cash $172.1M.
FY2025 GAAP net loss $183.1M ($1.56 diluted) vs $215.4M loss in FY2024; non-GAAP loss $159.2M.
Pipeline: tagmokitug (CCR8) trials in HNSCC, GI, ESCC, CRC; casdozokitug (IL-27) Phase 2 in 1L uHCC; data readouts in mid-2026.
Equity financings: ~$7.9M net from Oct 2025 offering; ~$47.0M net from Feb 2026 public offering.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Coherus Oncology, Inc. reported the years ended December 31, 2025 results: revenue $42.2 million.

Period: the years ended December 31, 2025
Revenue: $42.2 million
Result: reported results

Exact text from the filing

Net revenue from continuing operations was $12.7 million and $7.7 million during the three months ended December 31, 2025 and 2024, respectively, and $42.2 million and $26.4 million during the years ended December 31, 2025 and 2024, respectively.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Coherus Oncology, Inc. reported the three months ended December 31, 2025 results: revenue $12.7 million.

Period: the three months ended December 31, 2025
Revenue: $12.7 million
Result: reported results

Exact text from the filing

Net revenue from continuing operations was $12.7 million and $7.7 million during the three months ended December 31, 2025 and 2024, respectively, and $42.2 million and $26.4 million during the years ended December 31, 2025 and 2024, respectively.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Coherus Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-025293

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.